Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease a feasibility study

Journal of Applied Clinical Medical Physics

Volumn 11, Issue 1, 2010, Pages 77-87

  Vlachaki, Maria T ^a   Kumar, Sanath ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

3D CRT; Helical tomotherapy; Hodgkin's disease

Indexed keywords

EID: 77954301078     PISSN: None     EISSN: 15269914     Source Type: Journal    
DOI: 10.1120/jacmp.v11i1.3042     Document Type: Article

References (40)

1. Hutchinson R, Fryer C, Davis P, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998;16(3):897-906.
2. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18(7):1500-07.
3. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765-71.
4. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14):3081-87.
5. Robison LL, Bhatia S. Late-effects among survivors of leukemia and lymphoma during childhood and adolescence. Br J Haematol. 2003;122(3):345-59.
6. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin Oncol. 1990;17(6):758-68.
7. Von der Weid NX. Adult life after surviving lymphoma in childhood. Support Care Cancer. 2008;16(4):339-45.
8. Ng AK, Bernardo M, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):1989-96.
9. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72(1):24-33.
10. Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys. 1993;20(6):1709-19.
11. Peñagaricano J, Moros E, Corry P, Saylors R, Ratanatharathorn V. Pediatric craniospinal axis irradiation with helical tomotherapy: patient outcome and lack of acute pulmonary toxicity. Int J Radiat Oncol Biol Phys. 2009;75(4):1155-61.
12. Kunos CA, Dobbins DC, Kulasekere R, Latimer B, Kinsella TJ. Comparison of helical tomotherapy versus conventional radiation to deliver craniospinal radiation. Technol Cancer Res Treat. 2008;7(3):227-33.
13. Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009;73(1):273-79.
14. Schultheiss TE, Wong J, Liu A, Olivera G, Somlo G. Image-guided total marrow and total lymphatic irradiation using helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;67(4):1259-67.
15. National Cancer Institute. A phase III groupwide study of dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin disease. Children's Oncology Group AHOD0031. Bethesda, MD: National Cancer Institute; 2009.
16. Nahum AE, Tait DM. Maximizing control by customized dose prescription for pelvic tumors. In: Breit A, editor. Advanced radiation therapy: tumor response monitoring and treatment planning. Heidelberg, Germany: Springer; 1992.
17. Okunieff P, Morgan D, Niemierko A, Suit HD. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys. 1995;32(4):1227-37.
18. Lyman, J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:S13-19.
19. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys.1989;16(6):1623-30.
20. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21(1):123-35.
21. Aoyama H, Westerly DC, Mackie TR, et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys. 2006;64(3):962-67.
22. Hodgson DC. Hodgkin lymphoma: the follow-up of long-term survivors. Hematol Oncol Clin North Am. 2008;22(2):233-44, 4.
23. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA. 2005;102(37):13040-045.
24. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005;106(10):3358-65.
25. Eng-Siew Koh, Tu Huan Tran, Mostafa Heydarian, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2:13.
26. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol. 2005;6(10):773-79.
27. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85(9):3227-32.
28. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109(5):1878-1886.
29. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol. 2006;24(36):5735-41.
30. Koh ES, Sun A, Tran TH, et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006;66(1):223-28.
31. Eifel PJ, Donaldson SS, Thomas PR. Response of growing bone to irradiation: a proposed late effects scoring system. Int J Radiat Oncol Biol Phys. 1995;31(5):1301-07.
32. Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys. 2005;62(1):198-206.
33. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65(1):1-7.
34. Girinsky T, van der Maazen R, Specht L, et al: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270-77.
35. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol. 2006;78(1):1-5.
36. Shirato H, Seppenwoolde Y, Kitamura K, Onimura R, Shimizu S. Intrafractional tumor motion: lung and liver. Semin Radiat Oncol. 2004;14(1):10-18.
37. Vlachaki M, Castellon I, Leite C, Perkins T, Ahmad S. Impact of respiratory gating using 4-dimensional computed tomography (4D-CT) on the dosimetry of tumor and normal tissues in patients with thoracic malignancies. Am J Clin Oncol. 2009;32(3):262-68.
38. Lujan AE, Larsen EW, Balter JM, Ten Harken RK. A method for incorporating organ motion due to breathing into 3D dose calculations. Med Phys. 1999;26(5):715-20.
39. Heinzerling JH, Anderson JF, Papiez L, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys. 2008;70(5):1571-78.
40. Kissick MW, Fenwick J, James JA, et al. The helical tomotherapy thread effect. Med Phys. 2005;32(5):1414-23.